Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Luxi Ye"'
Publikováno v:
Radiation Oncology, Vol 14, Iss 1, Pp 1-11 (2019)
Abstract Background To investigate the potential impact of fractionation regimes and overall treatment time (OTT) on lymphopenia during definitive radiotherapy (RT) and its associations with patient outcomes in non-small cell lung cancer (NSCLC). Met
Externí odkaz:
https://doaj.org/article/1884e4c768d64f3c8fa36e12863694ca
Autor:
Liqing Zou, Tiantian Guo, Luxi Ye, Yue Zhou, Li Chu, Xiao Chu, Jianjiao Ni, Zhengfei Zhu, Xi Yang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
BackgroundPulmonary large cell neuroendocrine cancer (LCNEC) is commonly classified as non-small cell lung cancer (NSCLC). Even for stage I disease, after surgery the survival is always poor, but clinical research on LCNEC is scant and always with un
Externí odkaz:
https://doaj.org/article/c15d01d992d54e3d9cb189d4f7b5a2f9
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Regulatory T cells (Tregs), which have long been recognized as essential regulators of both inflammation and autoimmunity, also impede effective antitumor immune response due to their immunosuppressive properties. Combined radiotherapy and immunother
Externí odkaz:
https://doaj.org/article/3fbb6c8570a44b2d8541387d3f295a1b
Autor:
Shiming, Shi, Biao, Wang, Jinglei, Wan, Lina, Song, Guiqi, Zhu, Junxian, Du, Luxi, Ye, Qianqian, Zhao, Jialiang, Cai, Qing, Chen, Kun, Xiao, Jian, He, Lei, Yu, Zhi, Dai
Publikováno v:
Acta Biochimica et Biophysica Sinica. 54:1008-1020
Expression of transmembrane protein 106A (TMEM106A) has been reported to be dysregulated in several types of cancers. However, the role of TMEM106A in hepatocellular carcinoma (HCC) is still unknown. In the present study, we demonstrate that TMEM106A
The "Fridays for Future" movement works worldwide to ensure compliance with the climate goals set out in the UN World Climate Agreement in 2015 and to stop the progression of man-made climate change. It was brought to life in 2018 by the Swede Greta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97b06a19c5bc20a3f0b97fe8eafe246e
Autor:
Yuan Li, Zhengfei Zhu, Yang Zhao, Wanqin Zeng, Xiao Chu, Jianjiao Ni, Tiantian Guo, Wen Yu, Liqing Zou, Shengping Wang, Q. Liu, Yue Zhou, Yida Li, Luxi Ye, Ya Zeng, Li Chu, Shuyan Li, Xi Yang, Fan Yu
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:804-815
Purpose As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a high potency for controlling brain metastases (BMs) from EGFR-mutant
Autor:
Xi Yang, Tiantian Guo, Liqing Zou, Zhengfei Zhu, Yida Li, Luxi Ye, Xiao Chu, Jianjiao Ni, Li Chu
Publikováno v:
Journal of Inflammation Research
Yida Li,1,2,* Liqing Zou,1,2,* Li Chu,1,2 Luxi Ye,1,2 Jianjiao Ni,1,2 Xiao Chu,1,2 Tiantian Guo,1,2 Xi Yang,1,2 Zhengfei Zhu1,2 1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, Peopleâs Republic of Ch
Autor:
Zhengfei Zhu, Weigang Hu, Lijun Zhou, Xiao-Fei Zhang, Luxi Ye, Q. Liu, Xi Yang, Li Chu, Jie Lin, Lining Sun, Shengping Wang, Jiazhou Wang
Publikováno v:
Journal of Cancer
Background: Our previous work showed that para-aortic lymph node (PALN) metastasis was the major failure pattern in lower thoracic esophageal squamous cell carcinoma (LTESCC) patients who presented abdominal LN failure after curative surgery. We ther
Autor:
Ya Zeng, Shuyan Li, Yida Li, Fei Liang, Xiao Chu, Yang Zhao, Bo Wang, Liqing Zou, Shengping Wang, Q. Liu, Jinghan Qu, Li Chu, Fan Yu, Zhengfei Zhu, Yue Zhou, Xi Yang, Tiantian Guo, Jianjiao Ni, Luxi Ye
Publikováno v:
Lung Cancer. 150:178-185
Objectives Central nervous system (CNS) metastases are common complications in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) treated with EGFR-tyrosine kinase inhibitors (TKIs). However, for patients without baseli
Publikováno v:
Transl Lung Cancer Res
Based on the PACIFIC study, the standard care of unresectable locally advanced non-small cell lung cancer (LA-NSCLC) shifted from concurrent chemo-radiotherapy (CCRT) alone to CCRT followed by durvalumab consolidation in 2017. In the era of immunothe